Rejuvenate Bio, a medtech firm researching proven anti-aging strategies in animals and eventually applying them to humans, is raising growth capital on Wefunder, with the round scheduled to close next week.
According to the offering page, Rejuvenate Bio is raising more than $3.2 million under the Reg CF exemption. A concurrent funding round has already raised over $6 million and is matching the offering. The company is selling preferred equity held in an SPV at a $59.4 million pre-money valuation. The offering page indicates that more than 1,266 investors have backed the firm. The offering requires a minimum investment of $250 and a per-share price of $0.91. In total, the company reports having previously raised $36 million
Rejuvenate Bio is developing a gene therapy that works in dogs and is being extended for potential use in people. The “one-shot gene therapies that target the root cause of aging and chronic disease.” The treatment is said to be “reprogramming the body for youthful function.”
They report strong preclinical results: one therapy is said to repair cardiac damage while restoring metabolic health, and another is said to extend lifespan by several years.
The global gene therapy market is hot, reaching $9.59 billion in 2025. Some anticipate the sector will hit $74.78 billion by 2035. There is already a plethora of supplements and clinical claims that seek to extend a viable, healthy. This is only going to grow.
The founders are well established and have solid backgrounds that align with the firm’s ambitions.
Like most startups, the company is losing money. The Form C indicates they had around $3.3 million in cash on hand as of August 2026. For non-accredited investors, the terms are the same as for the ongoing Reg D.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!
